학술논문
Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study
Document Type
Article
Author
Source
In Journal of the American Academy of Dermatology March 2024 90(3):504-511
Subject
Language
ISSN
0190-9622